In a search for an agent giving rise to high level synergy we went on to examine the combination with an aminopeptidase inhibitor, tosedostat (CHR-2797), which we have recently shown to have potent anti-myeloma activity in vitro and in vivo [23, 24]. Here, CPQ is linked to plasma cell myeloma.